Custom Investing Search Tool

Monday, December 15, 2014

I sitll like Synta and heres another piece of good news

Synta Pharmaceuticals (NASDAQ:SNTA) has just announced preliminary results from an investigator-sponsored Phase I clinical trial of its flagship product ganetespib. The small study which was led and designed by researchers at New York University Langone Medical Center and Memorial Sloan Kettering Cancer Center evaluated ganetespib in combination with paclitaxel and trastuzumab in women with HER2+ metastatic breast cancer that was refractory to treatment with other HER2 inhibitors. The study enrolled six heavily pretreated patients who prior to entering the trial, receive a median of 3.5 anti-HER2 including trastuzumab, pertuzumab, and ado-trastuzumab emtansine. The trial was done to see if ganetespib could lead to a full or partial tumor response in addition to extending progression free survival. The results were decent. Of the five patients evaluable for efficacy, partial tumor response was observed in one patient who remains on study, and four patients achieved stable disease ranging in duration from 11 to 29 weeks. Median progression free survival was 19.4 weeks and the proportion of patients achieving objective response or stable disease greater than 24 weeks was 60%. Side effects were minimal.

When I previously covered Synta in depth, I had argued that...READ MORE

Dont give up on Response Genetics

Response Genetics (NASDAQ:RGDX) has just announced that it has received approval from the New York State Department of Health to offer, market and report results of its ResponseDX tests to healthcare providers in the State of New York. This is a huge announcement for the company. Why? Well because New York is the third most populated state in the U.S. and the addition of this license to provide testing here will most certainly contribute to the continued growth of the company's ResponseDX sales in 2015. In just the last quarter, the company hit another sales record with its ResponseDX line. I fully expect new sales records in 2015 on the back of this news.

When I covered Response Genetics in depth I laid out a clear analysis showing the turn around the company was undergoing. The last quarter was clearly an indication that the thesis was playing out. However, the stock has clearly moved in the opposite direction of the company. That said, I....READ MORE

Hecla mining and its quarter

Hecla Mining (NYSE:HL) just announced its third quarter operating results. All three of the company's mines performed well in the quarter helping to deliver a beat on revenue estimates although earnings missed estimates by $0.02. All three of the companies mines were producing splendidly and led to production of 2.9 million ounces of silver at a cash cost of about $5.43 per ounce. This was a whopping 25% increase year-over-year. Further the company also produced 42,501 ounces of gold around $900 an ounce which was a 15% production increase compared to last year. Revenues came in at $135 million, a 27% year-over-year rise. Net income was $3.5 million, or $0.01 per share, compared to a net loss of $8.6 million, or $0.03 per share for the third quarter last year. After special adjustments, the company saw a loss of a penny. In a sign of strength, the company did not bleed cash quarter-over-quarter as its cash and cash equivalents were unchanged at $222 million. Despite much lower metal prices, this was a...READ MORE

Western Asset Mortgage---Im shocked

Western Asset Mortgage (NYSE:WMC) has just reported its third quarter. I have to say the dividend king has shown it is not "immortal". While mREITs as a whole struggled in the third quarter, I wasn't just surprised - I was shocked - when I saw the numbers out of WMC. The company saw GAAP net income of just $26.1 million, or $0.63 per basic and diluted share. This compares to net income of $67.6 million, or $1.68 per basic and diluted share for the second quarter. That is an unbelievable decline. I really am in disbelief. Further disappointing was that WMC generated core earnings plus drop income of only $27.8 million, or $0.67 per basic and diluted share, failing to cover the $0.70 dividend. This compares to core earnings plus drop income of $40.0 million, or $1.00 per basic and diluted share for the second quarter. What about the key metrics of the company?

I'll be up front. The spread sucked. It got.....READ MORE

More on MeetMe's earnings

MeetMe (NASDAQ:MEET) just reported its third quarter earnings. And guess what? It actually turned a profit! MeetMe beat estimates on the top and bottom lines. It all stems from the innovations the company is implementing that have led to record user growth. Total revenue in the quarter was $11.6 million, up 15% from the third quarter of 2013. Mobile revenue was $6.7 million or 58% of the revenue and was up 128% from the third quarter of 2013. Mobile average revenue per user (ARPU) was $2.29, up 108% from $1.10 in the third quarter of 2013, and exceeded web ARPU of $1.01 for the fourth consecutive quarter. Mobile average revenue per daily active user ((ARPDAU)) was $0.082, up 105% from $0.040 in the third quarter of 2013.Adjusted EBITDA was $2.2 million, up 213% from $696,000 in the third quarter of 2013. This all led to the company actually turning a profit. Net income was $52,000 compared to a net loss of $1.5 million for the third quarter of 2013. What a turn-around indeed. Cash and equivalents totaled $15.6 million at the quarter's end following these earnings and a completed equity offering which provided the Company with net proceeds of $10.5 million.

When I last opined on MeetMe I clearly....READ MORE

Annaly Capital, stay the course

Annaly Capital (NYSE:NLY) has been a name that I have long followed. After the company recently reported its third quarter earnings I decided to pen an article to argue why I am not backing away from the stock. Sure it is a cyclical business. Timing buys in this stock over the long-term is key. We buy stock in mREITs for one of two reasons: to reinvest dividends over time to compound our investments, or to generate a source of income. Despite the stock shedding 40% plus since its highs, management remains effective and the current dividend is safe. The company is on the mend and is outcompeting many of its mREIT brethren as I will outline in this article. Its quarter was quite strong, with few weak points.

First.....READ MORE

Popular Posts

Translate

HOT STOCKS!!!